Podcasts about implantable

Association Between COVID-19 Vaccination and Atrial Arrhythmias in Individuals with Cardiac Implantable Electronic Devices   Guest: Malini Madhavan, M.B.B.S. Host: Anthony H. Kashou, M.D.   In a study of over 7000 individuals with a cardiac implanted device in the Biotronik CERTITUDE registry, the burden of device detected AF was noted to be higher in the 3 months after covid vaccination compared to the 3 months preceding vaccination. A similar trend was observed for Influenza vaccinated individuals. However, when comparing a propensity matched group of controls without COVID vaccination, the trend towards increased burden of AF was similar in the 2 groups. This led the authors to conclude that the observed increase in AF burden represents the natural progression of AF risk rather than vaccine related changes.   Topics Discussed: The study of atrial fibrillation burden after COVID vaccination, including the conclusion. How the incidence of AF after COVID 19 vaccination compares to that after influenza vaccination. Other studies that have investigated arrhythmia occurrence after COVID vaccination. Safety for patients with cardiovascular disease to get vaccinated for COVID 19. References: https://www.heartrhythmjournal.com/article/S1547-5271(22)00914-6/fulltext https://onlinelibrary.wiley.com/doi/epdf/10.1111/jce.16372 https://pmc.ncbi.nlm.nih.gov/articles/PMC9175153/#:~:text=A%20total%20of%202611%20events,COVID%2D19%20vaccine%20doses%20administered Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Join host Michael S. Lloyd, MD,FHRS and episode participants Karim Benali, MD, PhD and Reinoud Knops, MD, PhD as they discuss this recent article that focuses on unique aspects of implantable defibrillators as experienced by young patients. The team gathered in person for this lively discussion at EHRA 2025 in Vienna. Bonus video footage of the episode is available on heartrhythm365.org. https://www.hrsonline.org/education/TheLead https://www.ahajournals.org/doi/10.1161/CIRCEP.124.013365 Host Disclosure(s): M. Lloyd: Honoraria/Speaking/Consulting: Medtronic, Arga Medtech, Circa Scientific Membership on Advisory Committees: Boston Scientific   Contributor Disclosure(s): K. Benali: Nothing to disclose. R. Knops: Honoraria/Speaking/Consulting: Boston Scientific, Metronic, Inc., Cairdac, Abbott Membership on Advisory Committees: Kestra, Inc.

The wide array of cardiovascular implantable electronic devices (CIEDs) s may lead to confusion as to which one to use in what circumstances. Differentiating defibrillators, pacemakers, and loop recorders--as well as accessing and utilizing the collected data--is covered by guest Erin Nordstrom, BSN, RN, PHN, CV-B. Related PCNA courses:Choosing the Right Cardiac Pacing Device: https://pcna.net/online-course/choosing-the-right-cardiac-pacing-device-heart-failure-interventions/ 12-Lead ECG in the Clinical Setting: https://pcna.net/online-course/interpreting-and-applying-the-12-lead-ecg-in-clinical-settings/Managment of Atrial Fibrillation: https://pcna.net/online-course/management-of-atrial-fibrillation-from-a-to-z/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, we are joined by Brent Lucas, CEO of Envoy Medical, to explore the future of hearing health and the groundbreaking technology behind fully implanted hearing devices.We discuss the hidden impact of hearing loss on mental health and cognitive decline, Apple's entry into the hearing aid market, and how Envoy Medical is disrupting the industry with innovative, 24/7 hearing solutions.Also, don't forget to subscribe to IE+ for premium insights and exclusive content!

CapeTalk’s Sara-Jayne Makwala King (in for Clarence Ford on Views and News) is joined by Esri van Pletzen from Hearo.See omnystudio.com/listener for privacy information.

Hearing technology is evolving, and fully implantable devices are becoming a reality. In this discussion, Brent Lucas, CEO of Envoy Medical, joins Shari Eberts to talk about the company's fully implantable hearing solutions, including the Esteem active middle ear implant and the Acclaim fully implantable cochlear implant, which is currently in clinical trials. Unlike traditional hearing aids and cochlear implants, these devices do not require an external component, allowing users to hear 24/7, even while sleeping or showering.The conversation also explores key trends in hearing technology, including increased competition and innovation in the space. With major tech players like Apple entering the market and advancements in consumer hearing solutions, the landscape of hearing care is shifting. Brent discusses how greater competition, choice, and awareness can help address hearing loss stigma and ensure that individuals have more options beyond traditional hearing aids.Additionally, Brent highlights the Hearing Device Coverage Clarification Act, legislation aimed at improving insurance coverage for fully implantable hearing devices. He emphasizes the importance of consumer advocacy and encourages individuals to research all available hearing solutions to find the best option for their unique needs.Be sure to subscribe to our YouTube channel for the latest episodes each week, and follow This Week in Hearing on LinkedIn and X (formerly Twitter): https://www.linkedin.com/company/this-week-in-hearing/ https://twitter.com/WeekinHearing

Our guest today is Evelyn Gamble.  Evelyn is a dedicated healthcare worker and passionate heart disease advocate. With a deep commitment to improving health outcomes, Evelyn uses her personal and professional experiences to raise awareness about heart health, particularly for young adults. As a strong voice for change, she aims to inspire others to take proactive steps in managing their heart health and to advocate for better care and resources for those affected by heart disease.     Definition: A heart arrhythmia, also known as a cardiac arrhythmia, is an abnormal rhythm of the heart. It occurs when the electrical impulses that control the heart's contractions do not function properly.    Causes:    Heart arrhythmias can be caused by a wide range of factors, including:    Heart disease (e.g., coronary artery disease, heart failure) Electrolyte imbalances (e.g., low potassium or magnesium) Certain medications (e.g., stimulants, caffeine) Thyroid disorders Damage to the Vagus Nerve Stress Genetics    Types:    There are many different types of heart arrhythmias, which can be classified based on the rate and rhythm of the heart:    Tachycardia: A rapid heart rate (over 100 beats per minute)    Bradycardia: A slow heart rate (under 60 beats per minute)    Atrial fibrillation: A quivering or irregular rhythm of the upper chambers of the heart (atria)    Ventricular fibrillation: A life-threatening rhythm where the lower chambers of the heart (ventricles) contract irregularly and chaotically    Premature beats: Extra heartbeats that occur early in the rhythm    Symptoms:    Some people with heart arrhythmias may not experience any symptoms. Others may have symptoms such as:    Palpitations (feeling like the heart is racing or fluttering), Chest pain or discomfort, Dizziness or lightheadedness, Fainting, and Shortness of breath.    Diagnosis and Treatment:    To diagnose a heart arrhythmia, your doctor will likely perform a physical exam, ask about your medical history, and take an electrocardiogram (ECG). Treatment options depend on the type and severity of the arrhythmia and may include:    Medications (e.g., beta-blockers, antiarrhythmics) Lifestyle changes (e.g., exercise, stress management) Surgery (e.g., ablation procedure) Implantable devices (e.g., pacemakers, defibrillators)    Outlook: The outlook for people with heart arrhythmias varies depending on the underlying cause and severity of the condition.

Imagine a world where the medical devices implanted in the body could communicate with doctors, providing vital data that could change the course of treatment and recovery. As technology advances, this scenario is becoming a reality. This breakthrough in medical technology not only promises enhanced patient outcomes but also pioneers a new approach to postoperative care, where data leads the way. In this week's episode, sponsored by Physician Growth Accelerator, we welcome Bill Hunter, President and CEO of Canary Medical, to discuss how his team is pioneering the transformation of medical devices into data-communicating tools. Bill shares insights on the development of smart implants that offer real-time feedback to both healthcare providers and patients, drastically altering expectations and outcomes in medical treatments. Join us as we explore the innovations driving this change and the future possibilities of implant technology. What we discuss in the episode: How implantable devices are being designed to communicate health data The impact of real-time data feedback from implants on post-operative care Future directions for smart implants in medical technology Case studies demonstrating the effectiveness of data-driven patient care Resources from this episode:  Get the free MedTech Talk Tracks for Action Physician Growth Accelerator Canary Medical Social Media:  Connect with Bill on LinkedIn Connect with Zed on LinkedIn Connect with Clark on LinkedIn

In this episode, Dr. Valentin Fuster discusses a groundbreaking study that uses machine learning to predict mortality and hospitalization risks in patients with implantable cardioverter defibrillators (ICDs). By leveraging large datasets and time-varying ICD data, the study developed a robust predictive model, though challenges remain regarding data gaps and its applicability to diverse patient populations.

Brent Lucas, CEO of Envoy Medical, highlights the lack of innovation in hearing aids and the need to better address hearing health. Envoy has developed fully implanted hearing devices that provide 24/7 hearing assistance without the need for daily recharging of the battery.  With the introduction of over-the-counter hearing aids and the advanced Apple AirPods Pro 2, customer options have been expanded, making it easier to address some forms of hearing loss. Implanted devices eliminate the limitations of external hearing aids and reduce the impact of hearing loss on their daily lives. Brent explains, "Part of the problem in the hearing loss industry has been that it's not well understood. So there has not been a great deal of competition and innovation in the hearing loss world. Most of us have thought about hearing loss and how it's addressed by looking to our grandparents, the elders. Plenty of people joke about our dads or our grandfathers not being able to hear our grandmothers. When I tell people I'm in the hearing industry, the first thing that they say is, I can't hear you. And I always fall for it. And I say, I'm in the hearing industry, and they come clean that it was a joke. At the end of the day, there are unmet needs in finding solutions for people that are not just the status quo. That's really where Envoy Medical is building products that are fully implanted, in a sense, a better life because they're not tied to their hearing loss." "Right now, the current solutions on the market are all external products that need to be taken off at night or around water in the shower, during strenuous activity, working out, sweating too much, that sort of thing. You have to take your external device off. Our devices are fully implanted, meaning you can be capable of hearing 24/7, hearing all day, every day. We think that's the right thing to do for a patient because your hearing loss, after all, is a 24-hour problem. It shouldn't be that your solution is only on for part of the day."  #EnvoyMedical #HearingLoss #Acclaim #HearingAids #CochlearImplant $COCH #HearingHealth  envoymedical.com Listen to the podcast here

Brent Lucas, CEO of Envoy Medical, highlights the lack of innovation in hearing aids and the need to better address hearing health. Envoy has developed fully implanted hearing devices that provide 24/7 hearing assistance without the need for daily recharging of the battery.  With the introduction of over-the-counter hearing aids and the advanced Apple AirPods Pro 2, customer options have been expanded, making it easier to address some forms of hearing loss. Implanted devices eliminate the limitations of external hearing aids and reduce the impact of hearing loss on their daily lives. Brent explains, "Part of the problem in the hearing loss industry has been that it's not well understood. So there has not been a great deal of competition and innovation in the hearing loss world. Most of us have thought about hearing loss and how it's addressed by looking to our grandparents, the elders. Plenty of people joke about our dads or our grandfathers not being able to hear our grandmothers. When I tell people I'm in the hearing industry, the first thing that they say is, I can't hear you. And I always fall for it. And I say, I'm in the hearing industry, and they come clean that it was a joke. At the end of the day, there are unmet needs in finding solutions for people that are not just the status quo. That's really where Envoy Medical is building products that are fully implanted, in a sense, a better life because they're not tied to their hearing loss." "Right now, the current solutions on the market are all external products that need to be taken off at night or around water in the shower, during strenuous activity, working out, sweating too much, that sort of thing. You have to take your external device off. Our devices are fully implanted, meaning you can be capable of hearing 24/7, hearing all day, every day. We think that's the right thing to do for a patient because your hearing loss, after all, is a 24-hour problem. It shouldn't be that your solution is only on for part of the day."  #EnvoyMedical #HearingLoss #Acclaim #HearingAids #CochlearImplant $COCH #HearingHealth  envoymedical.com Download the transcript here

Send us a textIt's already Episode 20 of Season 2 as we roll into winter 2024.Again this week the boy's are lucky to have two Guests Bethany Keime and Charlie Kirkman, both have different heart conditions, Bathany and twin sister Hannah both suffer from Hypertropic Cardiomyopathy whilst Charlie has Arrhythmia.Hypertrophic cardiomyopathy is a condition in which muscle tissues of the heart become thickened without an obvious cause. The parts of the heart most commonly affected are the interventricular septum and the ventricles.This is  is most often caused by abnormal genes in the heart muscle. These genes cause the walls of the heart chamber (left ventricle) to become thicker than normal. The thickened walls may become stiff and this can reduce the amount of blood taken in and pumped out to the body with each heartbeat.How is hypertrophic cardiomyopathy treated?Activity limits. ...Preventing dehydration. ...Medicines to treat shortness of breath and chest pain. ...Medicines to help prevent abnormal heart rhythms. ...Anticoagulants. ...Septal myectomy. ...Alcohol septal ablation. ...Implantable cardioverter defibrillator (ICD).An Arrhythmia, or irregular heartbeat, is a problem with the rhythm or rate of your heartbeat. Your heart may beat too quickly, too slowly, or with an irregular rhythm. It is normal for your heart rate to speed up during physical activity and to slow down while resting or sleeping but with Arrhythmia this can be irregular anytime.While Arrhythmias can be a serious condition that can affect your health, there are also treatments available to help. By following a treatment plan and making heart healthy lifestyle changes, you can learn how to live with a cardiac arrhythmia.In today's Interview Bethany & Charlie tell us openly and honestly about their conditions from diagnosis to how the deal with it today and in everyday life.Bethany & sister Hannah are two remarkable twins who have taken this illness head on and realised there are others like themselves undiagnosed. Their experience as young teenagers soon discovered there was little information available and resorted to Google to explore their condition. Social Media Patient Community did not exist, so Bethany & Hannah set about correcting this by starting their own Social media presence "Heart Charged" in hope to reach out to those with this condition and those still to be diagnosed.They made us aware that as young women it was hard to get healthcare professionals to take them seriously with their health issues, simply sidelining them and saying "It's all part of growing up as a young Women"  It wasn't until a member of the family discovered they had hypertrophic cardiomyopathy that both Bethany & Hannah were then checked for this Condition.These young women have gone from strength to strength and this is how they met Charlie through Their social media connections and recent success with the "Sudden Cardiac Art" Exhibition in the UK, now destined for Southern California.#getheartcharged#charliekirkman# Stroke# Subarachnoid hemorrhage#Mediastinal Germ Cell Tumour#Prostate Cancer#Bronchiectasis#CharcotmarietoothDisease#Emphysema#The after life#Ghosts#Spirts#Ouija boards#Mediums#Psychics#Reincarnation#HeartTransplant#EbsteinsAnomaly#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#HealthcareCheck out our website at www.whostomanddick.com

Don't let sleep apnea disrupt your nights—or your health—any longer. Texas Sinus & Snoring (346-413-9313) offers a wide range of sleep disorder treatments, including Inspire therapy. Schedule a no-obligation consultation at https://texassinusandsnoring.com/services/sleep-apnea/inspire-sleep-therapy/ to see if Inspire therapy is right for you. Texas Sinus and Snoring City: Spring Address: 2940 Farm to Market 2920 Website: https://texassinusandsnoring.com/ Phone: +1 346 413 9313 Email: Info@texassinusandsnoring.com

Dr. Robert Gereau a professor of anesthesiology at Wash U School of Medicine and director of Wash U's Pain Center joins KMOX Health Editor Fred Bodimer.

Is your CPAP mask creating more sleep problems than it's supposed to solve? If so, the revolutionary Inspire sleep apnea device might be just right for you. Southern California Pulmonary and Sleep Disorders Medical Center can help you decide - call 805-557-9930 or visit https://sleepmd4u.com/ Southern California Pulmonary and Sleep Disorders Medical Center City: Thousand Oaks Address: 317 S. Moorpark Road Website: https://sleepmd4u.com Phone: +18055579930 Email: info@sleepmd4u.com

In today's episode, I sat down with Paul, T1D and endurance enthusiast. Paul and I talk about growing up at a early age with Diabetes, pre-technology. We also discuss Eversense, the implantable CGM and Affrezza, inhaled insulin. Paul's InstagramCoach Ken's Resources:Website: www.simplifyingdiabetes.comNewsletter Sign Up"More Than A1C" - My Signature Coaching ProgramThe Diabetes Nutrition Master CourseThe 5-Pillars Of Diabetes Success WorksheetSupport & Donate To The PodcastThe T1D Exchange Registry is a research study, conducted over time, for individuals with type 1 diabetes and their supporters. Participants volunteer to provide their data for Diabetes research. Once enrolled, Registry participants have the opportunity to sign up for other studies on various topics related to type 1 diabetes.You can make an impact on the future of Diabetes now! Fill out an online  survey and gain access to tons of new research and the online portal. It only takes 10-15 minutes.Don't forget to check out Ancient Bliss an herbal supplement company.Use Discount Code KEN20 for 20% off at check out.Have a question, send me a DM or email. I'd love to connect and answer any questions you have.You can find the show  on any platform you listen to your podcasts!Don't forget to click on that subscribe button and leave a 5-star review, so you're notified when new episode drop every week.Questions about diabetes, don't hesitate to reach out:Instagram: @CoachK3NInstagram: @thehealthydiabeticpodTwitter: @thehealthydpodTik Tok: @thehealthydiabeticpodFacebook: @Simplifying Life With DiabetesEmail: ken@simplifyingdiabetes.comPodcast Disclaimer: Nothing that you hear on The Healthy Diabetic Podcast should be considered medical advice or otherwise; please always consult your medical TEAM before making any changes to your Diabetes management.Support the show

In this episode, Dr. Valentin Fuster discusses a comprehensive review on the challenges and considerations of using implantable cardiography devices in patients with advanced chronic kidney disease and heart failure. Highlighting key findings from Dr. Cecilia Barca's research, he explores the nuanced interplay between these conditions and device efficacy, emphasizing the need for tailored patient evaluations and future studies to improve outcomes.

With David Duncker, Hannover Heart Rhythm Center, Hannover - Germany, and Giuseppe Boriani, Modena Polyclinic Modena University Hospital, Modena - Italy. This episode will tackle GDMT in patients with cardiac implantable electronic devices: Heart failure medication optimization, ICD indications, remote monitoring.  

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: A new study looks at insulin needs in men vs women, updates on stem cell transplants and a new look at COVID 19 and T1D plus a fully implantable CGM is announced. We'll also tell you about a T1D athlete drafted to the MLB. Lots more in this week's episode, full transcipt below.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Do men and women have different insulin requirements? A new study conducted across Europe says yes – women overall need less. Published in the Journal of Diabetes Science and Technology this looked at over 9,000 adults with type 1 diabetes using data from patients using the Diabeloop Generation 1 (DBLG1) hybrid closed-loop pump system. In this study, women needed 14-percent less insulin overall than men. These researchers say these findings have important implications for the practical management of insulin therapy and highlight the necessity of considering gender as a crucial factor in diabetes treatment. The treatment guidelines provided by American and European Diabetes Societies do not currently have gender-specific recommendations for insulin-weight ratios. The co-founder and Chief Scientific and Technical Officer for Diabeloop. “This study also highlights the capacity to discover new insights from big-data analysis of real-world data.” *Insulin Requirements According to Gender and Weight in a Population of 9036 Adult Persons With Type 1 Diabetes Using Closed-Loop Insulin Delivery, https://doi.org/10.1177/19322968241252366). https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/27419187/diabeloop-study-reveals-significative-gender-differences-in-insulin-requirements-for-type-1-diabetes-patients/   XX New drug therapy in those lucky diabetic mice boosted insulin-producing cells by 700% over three months, effectively reversing the disease. Scientists at Mount Sinai and City of Hope have been able to grow new beta cells in the body, in a matter of months. The therapy involved a combination of two drugs: one is harmine, a natural molecule found in certain plants, which works to inhibit an enzyme called DYRK1A found in beta cells. The second is a GLP1 receptor agonist. The latter is a class of diabetes drug that includes Ozempic, The researchers tested the therapy in mouse models of type 1 and 2 diabetes.. The signs of the disease quickly reversed, and stayed that way even a month after stopping the treatment.   The results are intriguing, but of course being an animal study means there's still much more work to be done before it could find clinical use. So far, harmine alone has recently undergone a phase 1 clinical trial in humans to test its safety and tolerability, while other DYRK1A inhibitors are planned for trials in humans next year. https://newatlas.com/medical/diabetes-reversing-drug-boosts-insulin-producing-cells/ XX Stem cell–derived beta-cell replacement therapy continues to show benefit in people with type 1 diabetes at a high risk for severe hypoglycemia. New info from Vertex shows that of a total 17 patients who received a full dose of their  investigational allogeneic stem cell–derived, fully differentiated pancreatic islet cell replacement therapy (VX-880), three, thus far, have achieved the primary study efficacy endpoint of elimination of severe hypoglycemic episodes with A1c < 7% at 1 year and the secondary endpoint of insulin independence. Others are on the same trajectory, Piotr Witkowski, MD, PhD, professor of surgery at The University of Chicago, Chicago, said at the recent American Diabetes Association (ADA) 84th Scientific Sessions. In his presentation, Witkowski also provided details about the deaths of two study participants that the company had announced in January 2024, neither of which were related to the VX-880 product. In fact, there have been no severe adverse events related to the product itself, with most due to either the infusion procedure or the immunosuppression. "These data highlight the curative potential of VX-880 in people living with type 1 diabetes and support further evaluation of VX-880 toward pivotal development," Witkowski said. For now, patients selected for the study are those who experience frequent severe hypoglycemia deemed to be a greater risk to the patient than that of immunosuppression. However, Ahn pointed out, "With VX-880, the obvious fly in the ointment is the need for immunosuppression which carries significant risk…There are multiple solutions being proposed, but we are still waiting for data as promising as the initial Vertex data is on that front." https://www.medscape.com/viewarticle/stem-cell-derived-islets-continue-show-benefit-t1d-2024a1000cx1 XX Still lots of COVID studies coming in about type 1. A German study suggests COVID 19 may speed up progression of existing but presymptomatic T1D in kids. These researchers had been screening and following children in an early presymptomatic stage of type 1 diabetes for several years. They noticed an increase in the numbers of Incidence of clinical type 1 diabetes nearly doubled after the pandemic started. "We know that the virus can infect the pancreatic islets so it could be causing damage or change in the beta cells that make insulin," said Ziegler when discussing possible mechanisms behind this association. "Second, there is generalized inflammation during the infection and there may be a stimulation of the immune response. Third, there could be metabolic stress from the infection that affects the beta cells that make insulin. To dive into this topic, youth were identified in the German Fr1da-screening program from 2015 to 2023. All patients had presymptomatic diabetes defined as persistent, confirmed positive results for two or more islet autoantibodies. Their progression was monitored at 3- to 6-month intervals. Clinical type 1 diabetes was defined according to American Diabetes Association   COVID infection was either self-reported via the family or identified with SARS-CoV-2 antibodies were confirmed in blood samples collected at study visits.   Vaccination against COVID-19 may be one way to protect presymptomatic type 1 diabetes youth from progression, Ziegler added. She said her group is currently testing whether COVID-19 vaccination can reduce new-onset, presymptomatic type 1 diabetes in a clinical trial  of children with genetic risk factors for the condition. https://www.medpagetoday.com/endocrinology/type1diabetes/111084 XX The FDA says no – for now - to Novo Nordisk's weekly insulin.  This has been approved in Canada and should be available there shortly. But the FDA says it wants more information related to the manufacturing process and the type 1 diabetes indication to complete the review. Novo said it does not expect to be able to fulfil the requests this year, and that it will work closely with the FDA regarding the next steps. The regulator's decision follows its outside panel's vote against the use of the weekly insulin icodec, in patients with type 1 diabetes due to risks of low blood sugar. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-novo-nordisks-weekly-insulin-2024-07-10/ XX A couple of weeks ago we spoke to the attorneys taking on CGM monitronig in schools. They've helped a family in Connecticut and set a precdent.  A child with autism and diabetes was not getting reasonable accommodations under the federal Americans with Disabilities Act in a public preschool program. I'll link up the press release from the DOJ but this family wasn't getting any support and it just wasn't safe. The lawyers here tell me the ruling and settlement is just going to help them going forward as they try to make schools complient with CGM as a reasonable  accomodatin. https://www.justice.gov/usao-ct/pr/aba-therapy-provider-make-changes-comply-americans-disabilities-act   XX Ozempic could lower the risk of dementia and a range of other mental problems compared with other existing treatments for patients with diabetes. What's more, researchers found that Ozempic cut nicotine dependence in those patients.   This study relied on medical records from more than 100,000 U.S. diabetes patients, including more than 20,000 who were prescribed semaglutide between December 2017 and May 2021. After a year, patients who took Ozempic had a 48% lower risk of developing dementia than those on Januvia. The risk in Ozempic patients was also 37% lower than those who took Glucotrol and 9% lower than those on Jardiance. Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. But the authors emphasized that the analysis is observational. The results need to be replicated in a controlled trial that assigns patients to randomly take Ozempic and the other drugs, according to Dr. Max Taquet, another Oxford clinical lecturer and senior study author. https://www.cnbc.com/2024/07/16/healthy-returns-ozempic-may-lower-dementia-risk-nicotine-use.html XX   Edgepark Commercial XX The Omnipod 5 with Dexcom G7 integration is now available through select pharmacies with full availability expected in the fall.   The System uses new Pods that are compatible with both Dexcom G6 and G7, but the prescription code will stay the same as the current Omnipod 5 Pods. This means the community will have similar insurance coverage and access to what they have with Omnipod 5 today.   If you're looking to start on Omnipod 5 and you're currently using Dexcom G7, your doctor will need to send a prescription for both the Omnipod 5 Intro Kit and Omnipod 5 Pods, compatible with Dexcom G6-G7, to ASPN Pharmacies.   You can learn more at https://www.omnipod.com/innovation/dexcom-g7.   If you are already using Omnipod 5, you will get the new Pods compatible with Dexcom G6 and G7 through your Pod refills. You do not need a new prescription. The week of July 29th, you will receive a free software update for the Omnipod 5 App to your Controller or compatible Android smartphone which is needed to use the System with Dexcom G7. Accept the update. We recommend you continue to use your current Omnipod 5 Pods and Dexcom G6 supplies until the new Pods compatible with Omnipod 5 with Dexcom G6-G7 are available at your preferred pharmacy.   We'll email our users when the new Pods are available in most pharmacies.   You can learn more at https://www.omnipod.com/innovation/new-compatible-devices   XX Big promises about long-term implantable blood glucose monitor from a company called Focus. They say they're partnering with Glucotrack to quote - transform how people with diabetes interact with their condition. They're not calling this a CGM – rather it's a CBGM, continuous blood glucose monitor because it will measure glucose levels in blood, not in interstital fluid like CGMs do. They company says this is a fully subdermal location, with no external wearable. In preclinical studies, the CBGM has a MARD of 4.7% at day 90. That is MUCH lower than CGMs on the market – Dexcom and Libre are in the low 8s right now. BUT.. it hasn't been fully tested in people yet. Human clinical trials are set to start later this year. https://www.drugdeliverybusiness.com/focus-collaborates-glucotrack-implantable-cbgm/ XX Big congrats to Jamie Ferrer (Chy-may Fer-rare) On Monday, Ferrer's dream was realized when the Twins selected the Florida State outfielder in the fourth round (No. 126 overall) during Day 2 of the MLB Draft. Minnesota vice president of amateur scouting Sean Johnson said the club had its eyes on Ferrer since high school. “Recently, I was in Orlando at a conference called, “Friends for Life with CWD [Children with Diabetes],” and we had an event that was a sports day. … Kids would come up to me and either them or their families would ask me how I dealt with this [or that],” Ferrer said. “And seeing their faces light up whenever I said I was diagnosed at three and I played college baseball. … You hear people tell you no and that you can't do this because you have Type 1 diabetes … So why not inspire as many people as I can?”   “I'm super proud of being a Type 1 athlete, and it's something that I'll never shy away from talking about or showing off my insulin pump because it's who I am and it's something that I've had to deal with my entire life.” https://www.mlb.com/news/jaime-ferrer-selected-no-126-overall-by-twins-in-2024-mlb-draft XX Join us again soon!

Broadcast from KSQD, Santa Cruz on 7-11-2024 Dr. Dawn answers a caller's question about vitamin D supplementation, explaining its importance for bone health, mood regulation, and immune function. She discusses the physiological processes involving vitamin D and recommends getting blood levels checked. A second caller asks about the safety of Stevia as a sweetener. Dr. Dawn explains the importance of examining original sources for health claims and discusses the challenges of determining causality in nutrition studies. She compares various artificial sweeteners and suggests moderation in their use. Dr. Dawn provides a health alert about a measles exposure in Santa Cruz, describing symptoms to watch for and emphasizing the importance of vaccination. She shares personal anecdotes about the dangers of measles. An email from a listener about atrial fibrillation is addressed. Dr. Dawn discusses the risks associated with atrial fibrillation, blood thinners, and the Watchman device. She emphasizes the importance of stress reduction and suggests alternatives to invasive procedures. Dr. Dawn comments on a recent retraction of a key Alzheimer's study, discussing the implications for Alzheimer's research and treatment development. A new development in baby formula is discussed, involving genetically modified plants producing human milk oligosaccharides for improved infant nutrition. Dr. Dawn responds to an email about lipoprotein A and cardiovascular risk, discussing risk factors, the importance of inflammation reduction and omega-3 fatty acid supplementation. The show concludes with a mention of myFooddata.com, a nutrition information website recommended by a listener. Throughout the show, Dr. Dawn emphasizes the importance of critical thinking about medical information, considering economic drivers in healthcare, and focusing on lifestyle factors for overall health.

Venous closure devices, GLP1-s linked to blindness and cancer, resisting the urge to do an ECG, and transcatheter edge-to-edge repair (TEER) for secondary mitral regurgitation are the topics discussed this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Venous vascular closure system vs. figure-of-eight suture following atrial fibrillation ablation: the STYLE-AF Study https://doi.org/10.1093/europace/euae105 II GLP1-s and Blindness Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255 Locke Twitter  https://x.com/doc_BLocke/status/1808972226655629610 When to Start a Statin Is a Preference-Sensitive Decision https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029808 III GLP1-s and Cancer Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820833 IV Screening ECG Routine Electrocardiogram Screening and Cardiovascular Disease Events in Adultshttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2820721 Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP)  https://doi.org/10.1016/S0140-6736(21)01637-8 Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study) https://doi.org/10.1016/S0140-6736(21)01698-6 IV TEER for Secondary Mitral Regurgitation Randomized investigation of the MitraClip device in heart failure: Design and rationale of the RESHAPE-HF2 trial design https://doi.org/10.1002/ejhf.3247 Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.3286 Jun 21, 2024 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1001237 Stats Blog https://www.r-bloggers.com/2023/07/the-benjamini-hochberg-procedure-fdr-and-p-value-adjusted-explained/ You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

I spoke with Paul Reid, an outdoor T1D content creator, and user of the Eversense Implantable CGM. He shares his experience with the Eversense E3 sensor so far, explains the procedure process, accuracy and calibrations, and explains why Eversense is wildly different from any CGM system on the market.   Get Skin Grip patches (10% off w/ JUSTIN10) Thanks to our sponsor, Skin Grip. Code won't combine with other promos.   Fill out T1D Exchange Registry    Join Patreon for Exclusive Content | Join Diabetech Community Discord   Watch our other content: Instagram | Tik Tok | YouTube | Facebook   Follow Paul   Learn more about Eversense   Send us Feedback & Join the Newsletter   DISCLAIMER: This podcast is not medical advice. Always consult with your doctor before making changes to your health care. 

Retractable sports fields are nothing new – but in Spain, they've found an incredibly innovative new way of storing and caring for the country's most revered plot of grass, a new, implantable light therapy could promote better healing in those suffering from spinal cord injuries, and on This Day in History - The Transcontinental Express makes its cross country journey in 83 hours. Retractable Sports Field (GNN) Implantable Light Therapy (AIChE) (GNN) Transcontinental Express (History) (The Historical Marker Database) Learn more about your ad choices. Visit megaphone.fm/adchoices

Are you aware of current guideline recommendations and best practices for managing patients with CIED infections? Credit available for this activity expires: 5/6/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000768?ecd=bdc_podcast_libsyn_mscpedu

Show Notes 12 April 2024All Medical Miracles this Week!Story 1: New self-powered throat patch could help people speak without vocal cords.Source: LiveScience.com Story by Rebecca SohnLink: https://www.livescience.com/health/new-self-powered-throat-patch-could-help-people-speak-without-vocal-cords  Story 2: A bioelectronic mesh capable of growing with cardiac tissues for comprehensive heart monitoring.Source: MedicalXpress.com Story by Daegan MillerLink: https://medicalxpress.com/news/2024-03-bioelectronic-mesh-capable-cardiac-tissues.htmlStory 3: Shape-shifting ultrasound stickers detect post-surgical complications - First-of-its-kind device ‘tags' an organ to monitor abnormal, life-threatening fluid leaks.Source: Northwestern University Story by Amanda MorrisLink: https://news.northwestern.edu/stories/2024/03/shape-shifting-ultrasound-stickers-detect-post-surgical-complications/Story 4: Implantable batteries can run on the body's own oxygen.Source: Phys.org Story by "Cell Press"Link: https://phys.org/news/2024-03-implantable-batteries-body-oxygen.htmlFor more info, interviews, reviews, news, radio, podcasts, video, and more, check out ComputerAmerica.com!

With Perry Elliott, University College London, London - United Kingdom of Great Britain & Northern Ireland & Athanasios Bakalakos, Barts Heart Centre, London - United Kingdom of Great Britain & Northern Ireland. Link to paper Link to editorial

Implantable cardioverter-defibrillators (ICD) are a technology that many people have, especially if they survived cardiac arrest or have a heart condition that causes dangerous heart rhythms.ICDs are a great technology, but at some point a decision may need to be made about continued use or turning it off. This show will help you understand the issues involved and five considerations for making this decision. In this Episode:00:00 – Our Sponsor: Tree of Life Memorials and Digital & Stone00:20 – Intro02:03 – Richard Lewis in “Curb Your Enthusiasm”05:31 – “Much Ado About Dying” Documentary Review08:48 – Recipe of the Week: Charleston Chewies11:35 – Overlooked No More: Beatrix Potter16:50 – ICDs and End of Life35:53 – “This Confusion” – a poem37:49 – OutroFollow us on Facebook | Instagram | Email us at mail@every1dies.orgClick on this link to Rate and Review our podcast!

Updates on Cardiac Implantable Electronic Device Infections: New Data Driving the Need to Treat and Beat Infection. Credit available for this activity expires: 03/15/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000403?ecd=bdc_podcast_libsyn_mscpedu  

Commentary by Dr. Candice Silversides

Commentary by Dr. Valentin Fuster

Show Notes: Black Mirror Tech: WEF “IMPLANTABLE TECHNOLOGIES” 2025 (4IR). {For those who wish to support the [Show] and its [Research] with Donations, please send funds to :$aigner2019(cashapp) or https://www.paypal.me/Aigner2019 or Zelle(1-617-821-3168).}

First up on this week's show: the future of science in Russia. We hear about how the country's scientists are split into two big groups: those that left Russia after the invasion of Ukraine and those that stayed behind. Freelance journalist Olga Dobrovidova talks with host Sarah Crespi about why so many have left, and the situation for those who remain.   Next on the show: miniature, battery-free bioelectronics. Jacob Robinson, a professor in the department of electrical and computer engineering at Rice University, discusses how medical implants could go battery-free by harvesting energy from the human body and many other potential innovations in store for these internal medical devices.   This week's episode was produced with help from Podigy.   About the Science Podcast   Authors: Sarah Crespi; Olga Dobrovidova   LINKS FOR MP3 META   Episode page: https://www.science.org/doi/10.1126/science.adm8195   About the Science Podcast: https://www.science.org/content/page/about-science-podcast

First up on this week's show: the future of science in Russia. We hear about how the country's scientists are split into two big groups: those that left Russia after the invasion of Ukraine and those that stayed behind. Freelance journalist Olga Dobrovidova talks with host Sarah Crespi about why so many have left, and the situation for those who remain.   Next on the show: miniature, battery-free bioelectronics. Jacob Robinson, a professor in the department of electrical and computer engineering at Rice University, discusses how medical implants could go battery-free by harvesting energy from the human body and many other potential innovations in store for these internal medical devices.   This week's episode was produced with help from Podigy.   About the Science Podcast   Authors: Sarah Crespi; Olga Dobrovidova   LINKS FOR MP3 META   Episode page: https://www.science.org/doi/10.1126/science.adm8195   About the Science Podcast: https://www.science.org/content/page/about-science-podcast

(0:50) - An implantable device could enable injection-free control of diabetes

In this  episode, host Dr. Sean Leahy engages in a captivating conversation with Dr. Katina Michael. Dr. Michael's unique journey, transitioning from the telecommunications industry to academia and technology/society research, sets the stage for a thought-provoking discussion.The conversation delves into a wide spectrum of emergent technologies, beginning with an exploration of the metaverse. Dr. Michael offers insights into its definition and current progress, while also pondering its future implications. A significant focus is directed towards the convergence of digital and biological technologies, particularly in the context of implantable tech. The episode also delves into crucial considerations regarding age-appropriate design and the ethical usage of these groundbreaking technologies.One of the central themes of the conversation revolves around the potential impacts of AI, specifically generative AI, on education. Dr. Michael underscores the importance of thoughtful, collaborative design and emphasizes the need to consider social embeddedness when developing new technologies. Her advocacy for a human-centered approach, which prioritizes consulting end users and empowering human agency, shines through the discussion.While recognizing the buzz and excitement surrounding these innovations, Dr. Michael encourages a balanced perspective of measured optimism. She urges listeners to think critically about how best to harness these tools for the benefit of society, making this episode a compelling exploration of the evolving technological landscape. Links & Resources Mentioned:Katina's ASU Bio: https://search.asu.edu/profile/3298186 Katina's TED Talks: Brain Implants: Hype or Hope and Microchipping PeopleThe Medium is the Massage by Marshall McLuhanNotebook LLM by Google

Implantable continuous glucose maker Glucotrack announced it has a new VP of marketing. Fast Five hosts Sean Whooley and Danielle Kirsh talk about the new VP and their career history that supports the appointment. Haemonetics is expanding its global presence by launching its vascular closure device in Europe. Find out which device is going global, how it works and what's next for Haemonetics. The FDA granted 510(k) clearance to ICU Medical's infusion pump and software. Whooley explains what the they do and some of the features that make patient monitoring seamless. Pediatric devices is an underserved market, and PolyVascular and CobiCure are looking to fix that with a new partnership for non-surgical pediatric heart valves. Hear more about the partnership and what kinds of resources and funding the companies have. Biotronik has implanted its next-gen pacemaker in its first patients. Whooley details what the Anmia Edge is designed for, what benefits it offers and what doctors think about the device. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

Today's guest is Chad Webb, Chief Technology Officer at Rhaeos. Founded in 2018, Rhaeos is a clinical stage medical device company developing FlowSense, a patent protected platform technology and a noninvasive wireless, wearable skin patch that can assess and monitor fluid flow subdermally throughout the body. The company is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. There is no technology available today that can easily assess CSF flow in shunts wirelessly, bedside, and without capital equipment until now. Chad began his technical career 16 years ago doing electronic test fixture design for a small tech start-up. Since then, he has held R&D positions in academia, government labs, startups, and Fortune100 companies. Most recently, he spent six years building global technology R&D programs in highly regulated industries at 3M, with roles in driving new technologies from lab concept to commercialization, new program development, trial execution, R&D strategy, intellectual property strategy and licensing, and acquisitions. He has >30 patents and patent applications, and 20 peer-reviewed papers, many of which form the foundation of wearable flow sensing technology. In the episode, Chad will talk about: The work Rhaeos are doing within Healthcare, The technology and data that brings the product to life, Day-to-day life of the tech team, What the near future holds for Rhaeos, Why Rhaeos is a great place to work

Dr. Lorraine Provencher interviews Dr. Kaweh Mansouri about the results of his study using EYEMATE-SC sensor to monitor IOP measurements in glaucoma patients. From Ophthalmology's “EYEMATE-SC Trial: Twelve-Month Safety, Performance, and Accuracy of a Suprachoroidal Sensor for Telemetric Measurement of Intraocular Pressure” EYEMATE-SC Trial: Twelve-Month Safety, Performance, and Accuracy of a Suprachoroidal Sensor for Telemetric Measurement of Intraocular Pressure. Szurman, PeterSzurman, Peter et al. Ophthalmology, Volume 130, Issue 3, 304 - 312

An implantable cardioverter defibrillator (ICD) is a medical device that monitors your heart and can deliver an electric shock to correct life-threatening arrhythmia and prevent sudden cardiac arrest. Dr. Mohamed Kanj talks about the safety and risks of activity with an ICD and different arrhythmias. He reviews findings from research that helps guide how doctors care for active patients with ICDs.

Want to make sure you stay on top of all things geriatrics? Go to http://PTonICE.com/resources to check out our Free eBooks, Lectures, & the MMOA Digest!  

Dr. Alex Germano // #GeriOnICE // www.ptonice.com 

AF screening, BNP, a new SGLT2 inhibitor, a sky-is-blue study, and the UK Mini Mitral surgical trial are discussed in this week's podcast This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I AF Screening - Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064361 - Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01698-6 - Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders https://www.jacc.org/doi/full/10.1016/j.jacc.2019.09.050 - Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care https://jamanetwork.com/journals/jamacardiology/fullarticle/2801362 - Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design https://doi.org/10.1093/europace/euw319 - Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068511/ II Frailty and GDMT of HFrEF Frailty Linked to Lower Use of Guideline Treatments in HFrEF https://www.medscape.com/viewarticle/993218 - Physical Frailty and Use of Guideline‐Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction https://www.ahajournals.org/doi/10.1161/JAHA.122.026844 III Sotagliflozin FDA Approves New Drug, Sotagliflozin, for Heart Failure https://www.medscape.com/viewarticle/992518 - Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease https://www.nejm.org/doi/full/10.1056/NEJMoa2030186 - Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2030183 IV Mini-Mitral Support for Minimally Invasive Mitral Valve Repair: Mini Mitral Published https://www.medscape.com/viewarticle/993191 - Minithoracotomy vs Conventional Sternotomy for Mitral Valve Repair https://jamanetwork.com/journals/jama/article-abstract/2805908 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact: news@medscape.net

Impella, digital health, low-value processes, are tricuspid valve interventions with pacing leads are the topics Dr. John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Impella Class I Recall FDA Class I Recall for Some Abiomed Impella Heart Pumps https://www.medscape.com/viewarticle/992845 - A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.112.098194 - Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction https://doi.org/10.1016/j.jacc.2016.10.022 https://www.sciencedirect.com/science/article/pii/S0735109716367675?via%3Dihub - The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.119.044007 - Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock https://jamanetwork.com/journals/jama/fullarticle/2761003 - Danish Cardiogenic Shock Trial (DanShock) https://clinicaltrials.gov/ct2/show/NCT01633502 II. Wearable Devices - Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805753 doi:10.1001/jamanetworkopen.2023.16634 - Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01698-6 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01698-6/fulltext - Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care https://jamanetwork.com/journals/jamacardiology/fullarticle/2801362 III. The Cost of Quality Measures - The Volume and Cost of Quality Metric Reporting https://jamanetwork.com/journals/jama/fullarticle/2805705 - Goodhart's law https://en.wikipedia.org/wiki/Goodhart%27s_law IV. Tricuspid Valve Interventions and Pacing Leads Leadless Dual-Chamber Pacemaker Clears Early Safety, Performance Hurdles https://www.medscape.com/viewarticle/992464 - Transcatheter Tricuspid Valve Replacement With the EVOQUE System: 1-Year Outcomes of a Multicenter, First-in-Human Experience https://www.jacc.org/doi/10.1016/j.jcin.2022.01.280 - Effects of Implantable Cardioverter-Defibrillator Leads on the Tricuspid Valve and Right Ventricle: A Randomized Comparison of Transvenous versus Subcutaneous Leads https://eppro01.ativ.me/src/EventPilot/php/express/web/planner.php?id=HRS23&utm_source=heartrhythm&utm_medium=nav-button&utm_campaign=hr23-webtracking - Management and Outcomes of Transvenous Pacing Leads in Patients Undergoing Transcatheter Tricuspid Valve Replacement https://www.jacc.org/doi/10.1016/j.jcin.2020.04.054 - TRILUMINATE trial -- Transcatheter Repair for Patients with Tricuspid Regurgitation https://www.nejm.org/doi/full/10.1056/NEJMoa2300525 https://www.nejm.org/doi/full/10.1056/NEJMoa2300525 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Un marcapasos ayuda a controlar el ritmo cardíaco irregular. Utiliza pulsos eléctricos que estimulan el corazón para que este lata a un ritmo normal.

Commentary by Dr. Valentin Fuster

In this episode, Dr. Aaron Carroll talks with Hugh Lee, associate professor of biomedical engineering and director of the Center for Implantable Devices at Purdue University. They discuss how research translates into new implantable medical devices, including a device Lee is working on that can sense when the wearer is experiencing an opioid overdose and deliver a dose of life-saving Naloxone, as well as how engineers can collaborate with clinicians to drive further innovation in the field. Transcript: bit.ly/3H3Qkjl This Healthcare Triage podcast episode is co-sponsored by Indiana University School of Medicine, whose mission is to advance health in the state of Indiana and beyond by promoting innovation and excellence in education, research, and patient care, and the Indiana Clinical and Translational Sciences Institute, a three way partnership among Indiana University, Purdue University and the University of Notre Dame, striving to make Indiana a healthier state by empowering research through pilot funding, research education and training. More information on the Indiana CTSI can be found by visiting IndianaCTSI.org.

Tom Ruggia, Samsara's CEO, talks about the innovative technology that improves the vision of people with untreatable retinal disorders. The discussion also covers the importance of partnerships, telemedicine and the human-centric approach.